LYEL, US55083R2031

Lyell Immunopharma stock: CMO sold 422 shares for taxes

Published on 10/30/2026 at 00:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lyell Immunopharma stock is in focus after its chief medical officer made an automatic tax-withholding sale. The filing also disclosed his remaining holding.

Insider sale and pipeline context

Lyell Immunopharma's chief medical officer sold shares automatically to cover tax withholding from vested restricted stock units.
The transaction left the executive with a direct holding in the company.

LYEL, US55083R2031, Illustration mit AI erstellt.

Lyell Immunopharma stock is in focus after Chief Medical Officer Jarrad Mattieu Aguirre sold shares in an automatic transaction linked to tax withholding. Investing.com, citing Reuters, reported the transaction on October 13, 2026.

Automatic tax-related transaction

The sale took place on October 12, 2026. Aguirre sold 422 common shares for a total of USD 3,641, with reported sale prices ranging from USD 8.54 to USD 8.63 per share.

The transaction was described as an automatic sale to cover tax withholding obligations arising from the settlement of vested restricted stock units. That distinction matters for investors because the reported purpose was administrative rather than a stated discretionary investment decision.

Remaining direct holding

Following the transaction, Aguirre directly held 19,857 Lyell Immunopharma shares, according to the report. The company is a clinical-stage biotechnology business developing cellular therapies for cancer.

The same report also referenced Lyell's recent LYL273 program update and the company's expectation of additional Phase 1/2 data in third-line or later relapsed or refractory metastatic colorectal cancer. It said an end-of-Phase 1 meeting was expected in 2027.